Agios Pharmaceuticals Inc (NASDAQ:AGIO ) and Celgene Corporation (NASDAQ:CELG) today made public their excitement after the U.S. Food and Drug Administration (FDA) accepted New Drug Application (NDA) for Celgene. That is most probably the best news for patients with refractory or relapsed acute myeloid leukemia (AML) .NDA has been served with a Prescription Drug User Fee Act. It was on late December that 2016 that Celgene winded up on its NDA submission.
Michael Pehl, who is the President for Hematology/Oncology for Celgene admittedly said that there was a growing unmet need for persons with refractory or relapsed AML and it was high time to do something more about it. The passing of the enasidenib NDA comes in as a great milestone and the company is hopeful that soon it will be able to give top medical solutions to persons struggling with the devastating disease.
Agios appreciates the NDA acceptance as well as enasidenib’s prioritized review and it has shown its intention to join hands with its partners Celgene and FDA to propel plans to come up with a high end therapy for refractory or relapsed AML with a mutation of IDH2.Agios is one of the top Biotech Stocks Picks and that may have played part towards obtaining the trust it received.
David Schenkein, who happens to be the managing director, as well as chief executive officer at Agios in a statement showed the great need to for continued efforts for the adoption of molecular profiling as well as the locating of the top targeted therapies such as enasidenib. The companies in this merger are very much concerned with these patients suffering from AML and they are relentless in their moves to find perfect solutions to this nature of complications.
Celgene Corporation is a high end company with its location in New Jersey .This biopharmaceutical provider over the years has been investing its resources in the development of innovative therapies that help in dealing with cancer complications among patients as well as in facing out the inflammatory complications.
On the other hand Agios is known to focus on research and development of medicines to help face out the rare forms of disease complications and also in the treatment of cancer among patients. It is of course true that the world is being faced with a lot of diseases, some of them being new outbreaks. However, scientists and researchers are doing all they can to help have enough to treat the ailing percentage of the population. Agios, one of the Best Biotech Stocks is a gift to persons suffering from the rare disease complications.